ZIOPHARM Oncology Stock Forecast, Price & News

ZIOPHARM Oncology (NASDAQ:ZIOP) Frequently Asked Questions

Is ZIOPHARM Oncology a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ZIOPHARM Oncology in the last twelve months. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" ZIOPHARM Oncology stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ZIOP, but not buy additional shares or sell existing shares.
View analyst ratings for ZIOPHARM Oncology or view top-rated stocks.

How has ZIOPHARM Oncology's stock been impacted by COVID-19 (Coronavirus)?

ZIOPHARM Oncology's stock was trading at $2.54 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ZIOP shares have decreased by 48.6% and is now trading at $1.3050.
View which stocks have been most impacted by COVID-19.

When is ZIOPHARM Oncology's next earnings date?

ZIOPHARM Oncology is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for ZIOPHARM Oncology.

How were ZIOPHARM Oncology's earnings last quarter?

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) issued its quarterly earnings results on Monday, November, 8th. The biotechnology company reported ($0.11) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.15) by $0.04. The biotechnology company had revenue of $0.40 million for the quarter. During the same period in the prior year, the business earned ($0.10) EPS.
View ZIOPHARM Oncology's earnings history.

What price target have analysts set for ZIOP?

4 brokerages have issued 1 year price targets for ZIOPHARM Oncology's shares. Their forecasts range from $2.00 to $5.00. On average, they anticipate ZIOPHARM Oncology's share price to reach $3.50 in the next twelve months. This suggests a possible upside of 168.2% from the stock's current price.
View analysts' price targets for ZIOPHARM Oncology or view top-rated stocks among Wall Street analysts.

Who are ZIOPHARM Oncology's key executives?

ZIOPHARM Oncology's management team includes the following people:

• Kevin S. Boyle, Chief Executive Officer & Director (LinkedIn Profile)
• Timothy M. Cunningham, Chief Financial Officer
• Lynn M. Ferrucci, EVP-Human Resources, Administration & IT
• Raffaele Baffa, Chief Medical Officer & Head-Research
• Eleanor M. de Groot, General Manager-Cell Therapy & Executive VP

Who are some of ZIOPHARM Oncology's key competitors?

Some companies that are related to ZIOPHARM Oncology include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Exact Sciences (EXAS), Repligen (RGEN), Novavax (NVAX), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX) and Exelixis (EXEL).
View all of ZIOP's competitors.

What other stocks do shareholders of ZIOPHARM Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ZIOPHARM Oncology investors own include Precigen (PGEN), Gilead Sciences (gild), OPKO Health (OPK), (CELG), Sangamo Therapeutics (SGMO), Ionis Pharmaceuticals (IONS), Amarin (AMRN), Inovio Pharmaceuticals (INO), Arena Pharmaceuticals (ARNA) and Immunomedics (IMMU).

What is ZIOPHARM Oncology's stock symbol?

ZIOPHARM Oncology trades on the NASDAQ under the ticker symbol "ZIOP."

Who are ZIOPHARM Oncology's major shareholders?

ZIOPHARM Oncology's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.86%), Geode Capital Management LLC (1.55%), Renaissance Technologies LLC (0.68%), Point72 Asset Management L.P. (0.63%), Two Sigma Advisers LP (0.49%) and Millennium Management LLC (0.45%). Company insiders that own ZIOPHARM Oncology stock include David M Md Mauney, Groot Eleanor De, Heidi Hagen, Jaime Vieser, Jill Buck, Kevin G Lafond, Kevin S Sr Boyle, Laurence James Neil Cooper and Robert Hadfield.
View institutional ownership trends for ZIOPHARM Oncology.

Which major investors are selling ZIOPHARM Oncology stock?

ZIOP stock was sold by a variety of institutional investors in the last quarter, including Citigroup Inc., Two Sigma Investments LP, Geode Capital Management LLC, Morgan Stanley, Dimensional Fund Advisors LP, Jane Street Group LLC, New York State Common Retirement Fund, and Oppenheimer & Co. Inc.. Company insiders that have sold ZIOPHARM Oncology company stock in the last year include Groot Eleanor De, Jill Buck, Kevin G Lafond, Laurence James Neil Cooper, and Robert Hadfield.
View insider buying and selling activity for ZIOPHARM Oncology or view top insider-selling stocks.

Which major investors are buying ZIOPHARM Oncology stock?

ZIOP stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Millennium Management LLC, BlackRock Inc., Renaissance Technologies LLC, Marshall Wace LLP, UBS Group AG, Tudor Investment Corp Et Al, and State Board of Administration of Florida Retirement System. Company insiders that have bought ZIOPHARM Oncology stock in the last two years include Heidi Hagen, Jaime Vieser, and Kevin S Sr Boyle.
View insider buying and selling activity for ZIOPHARM Oncology or or view top insider-buying stocks.

How do I buy shares of ZIOPHARM Oncology?

Shares of ZIOP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ZIOPHARM Oncology's stock price today?

One share of ZIOP stock can currently be purchased for approximately $1.31.

How much money does ZIOPHARM Oncology make?

ZIOPHARM Oncology has a market capitalization of $282.07 million and generates $150 thousand in revenue each year. The biotechnology company earns $-79.98 million in net income (profit) each year or ($0.43) on an earnings per share basis.

How many employees does ZIOPHARM Oncology have?

ZIOPHARM Oncology employs 105 workers across the globe.

When was ZIOPHARM Oncology founded?

ZIOPHARM Oncology was founded in 2005.

What is ZIOPHARM Oncology's official website?

The official website for ZIOPHARM Oncology is www.ziopharm.com.

Where are ZIOPHARM Oncology's headquarters?

ZIOPHARM Oncology is headquartered at ONE FIRST AVENUE PARRIS BUILDING 34, BOSTON MA, 02129.

How can I contact ZIOPHARM Oncology?

ZIOPHARM Oncology's mailing address is ONE FIRST AVENUE PARRIS BUILDING 34, BOSTON MA, 02129. The biotechnology company can be reached via phone at (617) 259-1970, via email at [email protected], or via fax at 617-241-2855.